Hims & Hers reported 2.4 million subscribers in Q1 FY25, a 38% YoY increase from 1.74 million in Q1 FY24. Personalized treatments now make up 58% of the subscriber base, with 70% of new users choosing customized care in Q1. Monthly online revenue per subscriber rose 50% YoY to $84, driven by high adoption of tailored daily treatments.
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.
The bulls have well defended Hims & Hers' recovery from the April 2025 bottom (near to our fair value estimates), thanks to the growing adoption of its personalized healthcare offerings. These have directly triggered the growing subscriber base/ Revenue per Average Subscriber, with the improved manufacturing/ operating scale contributing to the richer profit margins. This is significantly aided by the growing GLP-1 partnership and the regulatory exemption surrounding compounding personalization, lending support to the raised FY2025 guidance and ambitious 2030 targets.
Household & Personal Products Industry | Consumer Defensive Sector | Mr. Andrew Dudum CEO | XMUN Exchange | US4330001060 ISIN |
US Country | 1,637 Employees | - Last Dividend | - Last Split | 13 Sep 2019 IPO Date |
Hims & Hers Health, Inc., based in San Francisco, California, operates as a telehealth platform connecting consumers with licensed healthcare professionals across the United States, the United Kingdom, and other international locations. The company leverages its websites and mobile application to offer a variety of carefully selected health and wellness products and services, both on prescription and over-the-counter basis. Its business model focuses on providing convenient access to ongoing healthcare services, including prescription medication refills and consultations with healthcare providers, as well as a wide range of wellness products through direct sales and wholesale partnerships.